A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

Inclusion Criteria

• Inclusion Criteria: - Willing and able to provide written informed consent. - Male or female aged ≥18 years at the time of signing the informed consent. - Have one of the following histologically or cytologically confirmed locally advanced (unresectable) or metastatic solid tumor for which the Sponsor has an associated clinical study: - Head and neck cancer - Cervical cancer - Non-small cell lung cancer - HPV positive anogenital cancers - Sarcoma - Other cancers with a reasonable likelihood of expressing 1 or more antigens included in a TScan clinical trial, following approval by the TScan Medical Monitor or their delegate. - Willing to provide a buccal swab for HLA testing - Willing to provide a saliva sample to use as a normal control for the LOH assay - Have access to an adequate FFPE tumor block that is <8 months old or is willing to provide a fresh core-needle biopsy from a location deemed safe by the treating medical team. Exclusion Criteria: • Participants undergoing anticancer therapy with curative intent such as tumor surgical resection with or without neoadjuvant/adjuvant therapy, or definitive chemoradiation, unless they have locoregionally advanced disease and are expected to have a high risk of relapse after their curative intent therapy as determined by the treating investigator.